Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 43

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 43
---
ger, the Company’s senior management is intended to be newly constituted. The Board of Directors believes that the newly proposed members of the senior management are well suited to the position. Swiss law does not require the election of the senior management by the shareholders’ meeting. Nevertheless, the Board of Directors proposes that the extraordinary shareholders meeting approves, on an advisory basis, the election of the following persons to the senior management: Mr. Ronen Twito (Executive Chairman and Chief Executive Officer): for a short biography, see above. Prof. Michel Revel, MD, PhD (Chief Scientific Officer): for a short biography, see above. Dr. Kfir Molakandov, PhD (Vice President Research and Development):Dr. Kfir Molakandov has served as Vice President and Head of Research and Development at Kadimastem since January 2018, and he was previously a researcher at Kadimastem from January 2011 until December 2017. He received his B.A, M.Sc. in Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from Tel Aviv University, Israel. Prof. Ariel Revel, MD (Director of Medical Affairs):Professor Ariel Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served as a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a Professor of Medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009, and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April 2017 until April 2024, he served at the Assaf Harofeh Medical Center. On April 2017 until April 2021, he served as a Professor at Assaf Harofeh Medical Center. He began his medical career in August 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May 2017. Professor Revel received his PhD from Tel -AvivUniversity and an MD degree from the Hebrew University of Jerusalem, Israel. Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program):Dr. Eric Konofal has served as NLS’s Chief Scientific Officer since February 2021 and as its Interim Chief Medical Officer since January 2024. Dr. Konofal is an IP expert and co -found